Previous Close | 6.02 |
Open | 5.91 |
Bid | 6.33 x 800 |
Ask | 6.34 x 1200 |
Day's Range | 5.76 - 6.32 |
52 Week Range | 0.76 - 9.39 |
Volume | |
Avg. Volume | 2,244,403 |
Market Cap | 631.087M |
Beta (5Y Monthly) | 1.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.42 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for APLT
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.
Company Strengthens Balance Sheet and Advances Rare Disease Pipeline
NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 Announced positive results from 12-month interim analysis of govorestat in ongoing INSPIRE Phase 3 trial in SORD Deficiency; Company plans to request pre-NDA meeting with neurology division of FDA Strengthened balance sheet with $100 million Private Placement, expected to extend cash runway